anetumab ravtansine + cisplatin

Anetumab ravtansine + cisplatin is a combination therapy under clinical investigation primarily for mesothelin-expressing advanced solid tumors, notably cholangiocarcinoma. **Anetumab ravtansine** is an antibody-drug conjugate (ADC) composed of a fully human anti-mesothelin IgG1 monoclonal antibody conjugated to the cytotoxic maytansinoid tubulin inhibitor DM4. Upon binding to mesothelin—a cell-surface glycoprotein highly expressed in several tumor types—the conjugate is internalized and DM4 is released, resulting in intracellular disruption of microtubules and tumor cell apoptosis. **Cisplatin** is a platinum-based chemotherapy that exerts its antineoplastic effects through crosslinking of DNA, thereby inducing apoptosis. The combination aims to exploit targeted cytotoxic delivery via anetumab ravtansine while leveraging the DNA-damaging effects of cisplatin[1][6].